Kaleido Biosciences, Inc. (KLDO)

Apr 18, 2022 - KLDO was delisted (reason: ceased operations)
0.290
0.000 (0.00%)
At close: Apr 14, 2022 12:00 AM
0.300
0.010 (3.552%)
After-hours:Apr 14, 2022 7:59 PM EDT

Income Statement (Annual)

Millions USD. Fiscal year is Jan - Dec.
Year20212020201920182017
Revenue
1.10.98000
Revenue Growth (YoY)
13.23%----
Gross Profit
1.10.98000
Selling, General & Admin
20.9723.8822.4318.626.04
Research & Development
67.855.9764.2342.0620.99
Operating Expenses
88.7779.8586.6660.6827.03
Operating Income
-87.67-78.87-86.66-60.68-27.03
Interest Expense / Income
2.842.80.981.010.44
Other Expense / Income
-0.22-0.06-1.310.060.09
Pretax Income
-90.29-81.62-86.33-61.74-27.56
Net Income
-90.29-81.62-86.33-61.74-27.56
Net Income Common
-90.29-81.62-86.33-61.74-27.56
Shares Outstanding (Basic)
42332654
Shares Outstanding (Diluted)
42332654
Shares Change
25.14%30.14%403.18%14.29%-
EPS (Basic)
-2.16-2.44-3.36-12.09-6.17
EPS (Diluted)
-2.16-2.44-3.36-12.09-6.17
Free Cash Flow Per Share
-1.86-1.96-3.09-9.65-5.35
Gross Margin
100.00%100.00%---
Operating Margin
-7940.85%-8089.64%---
Profit Margin
-8178.26%-8371.28%---
Free Cash Flow Margin
-7045.74%-6722.26%---
EBITDA
-85.09-77-84.04-59.95-26.81
EBITDA Margin
-7707.61%-7896.92%---
EBIT
-87.45-78.82-85.35-60.74-27.12
EBIT Margin
-7921.20%-8083.90%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).